This is an excerpt of the January 3, 2018 PR...
Post# of 11802
(Total Views: 376)
Posted On: 08/13/2018 9:04:39 AM
This is an excerpt of the January 3, 2018 PR...
“2018 is expected to become a seminal year for DECN. It begins with the marketing of its launched GenSure!™ diabetic test strip, targeted for the patient population across the developing markets. The company will then, in rapid succession, introduce three new products, the GenChoice!™ test strip for worldwide distribution, GenPrecis!™ test strip and Precise meter, and the GenAccord!™ multiple-egress test strip that capitalizes on the GenPrecis!™ "full spread electro-chemistry technology." This intense activity begins January 15, 2018 with the global introduction of the GenSure!™ test strip. Following shortly thereafter, at the end of January 2018, the commencement of clinical trials for the GenChoice! test strip should culminate with the filing of 510K application filing for market clearance with the U.S. FDA in late February. International sales of GenChoice!™ are expected to begin in March 2018.
Additionally, the company intends to finalize its testing of the GenPrecis!™ test strip by January 28, and the GenPrecis!™ Precise meter by February 28. This GenPrecis!™ test strip is now compatible with two legacy meters sold internationally”.
So why would an investor not want a clear and concise update on status inc timing from the Company?
GenSure -Jan 2018 intro ?
GenChoice - Jan 2018 510 Filing?
GenChoice - Mar 2018 sales?
GenPrec - Jan 2018 test strip testing?
GenPrec - Feb 2018 meter testing?
Each of the above were 90 day milestones. Seems any company should have clear line of sight on these items.
As a shareholder I’m not interested in message board spin or attacks. As a shareholder I’m looking for results and if no results WHY? Frankly, redirecting resources to pets isn’t a viable reason no matter what some experts may tout.
“2018 is expected to become a seminal year for DECN. It begins with the marketing of its launched GenSure!™ diabetic test strip, targeted for the patient population across the developing markets. The company will then, in rapid succession, introduce three new products, the GenChoice!™ test strip for worldwide distribution, GenPrecis!™ test strip and Precise meter, and the GenAccord!™ multiple-egress test strip that capitalizes on the GenPrecis!™ "full spread electro-chemistry technology." This intense activity begins January 15, 2018 with the global introduction of the GenSure!™ test strip. Following shortly thereafter, at the end of January 2018, the commencement of clinical trials for the GenChoice! test strip should culminate with the filing of 510K application filing for market clearance with the U.S. FDA in late February. International sales of GenChoice!™ are expected to begin in March 2018.
Additionally, the company intends to finalize its testing of the GenPrecis!™ test strip by January 28, and the GenPrecis!™ Precise meter by February 28. This GenPrecis!™ test strip is now compatible with two legacy meters sold internationally”.
So why would an investor not want a clear and concise update on status inc timing from the Company?
GenSure -Jan 2018 intro ?
GenChoice - Jan 2018 510 Filing?
GenChoice - Mar 2018 sales?
GenPrec - Jan 2018 test strip testing?
GenPrec - Feb 2018 meter testing?
Each of the above were 90 day milestones. Seems any company should have clear line of sight on these items.
As a shareholder I’m not interested in message board spin or attacks. As a shareholder I’m looking for results and if no results WHY? Frankly, redirecting resources to pets isn’t a viable reason no matter what some experts may tout.
(1)
(0)Decision Diagnostics Corp (DECN) Stock Research Links
Scroll down for more posts ▼